Taken together, our data suggest that SchB has a beneficial effect to the treatment of NASH-related fibrosis, at least in part, by activating the Nrf2-dependent pathways. The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatohepatitis.